hydroxychloroquine has been researched along with Glomerulonephritis, Membranous in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Glomerulonephritis, Membranous: A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine could be an option for patients with membranous nephropathy seeking to achieve proteinuria reduction and anti-PLA2R antibody reduction in addition to optimized RAASi." | 8.12 | Effects of hydroxychloroquine on proteinuria in membranous nephropathy. ( Cheng, XY; Cheng, YJ; Cui, Z; Liu, G; Meng, LQ; Wang, F; Wang, X; Zhang, YM; Zhao, MH, 2022) |
| " Recommendations were either consistent or differences were of negligible clinical relevance for: indication for kidney biopsy, kidney biopsy interpretation, treatment targets, hydroxychloroquine dosing, first-line initial immunosuppressive therapy for active class III, IV (±V) LN, pregnancy in LN, LN in paediatric patients and LN patients with kidney failure." | 4.31 | The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. ( Anders, HJ; Bruchfeld, A; Fernández-Juárez, GM; Floege, J; Frangou, E; Goumenos, D; Kronbichler, A; Loutan, J; Segelmark, M; Stevens, KI; Tesar, V; Turkmen, K; van Kooten, C, 2023) |
| "Hydroxychloroquine could be an option for patients with membranous nephropathy seeking to achieve proteinuria reduction and anti-PLA2R antibody reduction in addition to optimized RAASi." | 4.12 | Effects of hydroxychloroquine on proteinuria in membranous nephropathy. ( Cheng, XY; Cheng, YJ; Cui, Z; Liu, G; Meng, LQ; Wang, F; Wang, X; Zhang, YM; Zhao, MH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YJ | 1 |
| Cheng, XY | 1 |
| Zhang, YM | 1 |
| Wang, F | 1 |
| Wang, X | 1 |
| Meng, LQ | 1 |
| Liu, G | 1 |
| Cui, Z | 1 |
| Zhao, MH | 1 |
| Anders, HJ | 1 |
| Loutan, J | 1 |
| Bruchfeld, A | 1 |
| Fernández-Juárez, GM | 1 |
| Floege, J | 1 |
| Goumenos, D | 1 |
| Turkmen, K | 1 |
| van Kooten, C | 1 |
| Frangou, E | 1 |
| Stevens, KI | 1 |
| Kronbichler, A | 1 |
| Segelmark, M | 1 |
| Tesar, V | 1 |
2 other studies available for hydroxychloroquine and Glomerulonephritis, Membranous
| Article | Year |
|---|---|
Effects of hydroxychloroquine on proteinuria in membranous nephropathy.
Topics: Autoantibodies; Female; Glomerulonephritis, Membranous; Humans; Hydroxychloroquine; Immunosuppressiv | 2022 |
The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021.
Topics: Biopsy; Child; Female; Glomerulonephritis, Membranous; Humans; Hydroxychloroquine; Immunosuppressive | 2023 |